adenocarcinoma of the lung
Showing 1 - 25 of >10,000
Local and Peripheral Immune Responsive Landscape Induced by
Not yet recruiting
- Lung Adenocarcinoma
- Local Cryoablation
- (no location specified)
Oct 24, 2023
Tumor Microenvironment
Active, not recruiting
- Lung Adenocarcinoma
- (no location specified)
Aug 5, 2023
Lung Adenocarcinoma Trial in Shijiazhuang (Tislelizumab,Platinum)
Recruiting
- Lung Adenocarcinoma
-
Shijiazhuang, Hebei, ChinaThe Fourth Hospital of Hebei Medical University (Hebei Tumor Hos
Sep 24, 2023
IA Lung Adenocarcinoma, Combined Segmentectomy Trial in Fuzhou (Patients receive subsegmentectomy)
Active, not recruiting
- IA Lung Adenocarcinoma
- Combined Segmentectomy
- Patients receive subsegmentectomy
-
Fuzhou, ChinaFujian Medical University Union Hospital
Aug 2, 2023
Invasiveness for Small-sized Lung Adenocarcinoma
Recruiting
- Lung Adenocarcinoma, Stage I
- Invasiveness diagnosis
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Apr 13, 2023
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma = 2cm
Recruiting
- Lung Adenocarcinoma
- Lobectomy with systemic lymph node dissection
- Segmentectomy with systemic lymph node dissection
-
Yangpu, Shanghai, ChinaShanghai Pulmonary Hospital
Apr 20, 2023
Novel Grading System of Resected Lung Adenocarcinoma
Recruiting
- Lung Adenocarcinoma
- +2 more
- Whole Slide Image based Deep Learning Signature
-
Zunyi, Guizhou, China
- +2 more
Jun 27, 2023
Intraoperative Frozen Section Pathology to Guide Surgical
Recruiting
- Lung Adenocarcinoma
- +2 more
- Surgical resection
-
Shanghai, Shanghai, ChinaFudan University Cancer Center
Mar 20, 2023
Intraoperative Frozen Section Pathology to Guide Surgical
Recruiting
- Lung Adenocarcinoma
- +2 more
- Surgical resection
-
Shanghai, Shanghai, ChinaFudan University Cancer Center
Mar 31, 2023
Lung Adenocarcinoma, Frozen Section, Sublobar Resection Trial in Shanghai (Sublobar Resection)
Recruiting
- Lung Adenocarcinoma
- +2 more
- Sublobar Resection
-
Shanghai, Shanghai, ChinaFudan University Cancer Center
Sep 4, 2023
Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)
Not yet recruiting
- Lung Adenocarcinoma
- +3 more
- Serplulimab and Bevacizumab injection
- (no location specified)
Dec 21, 2022
ALK-positive NSCLC Trial in Dallas (Ceritinib, Stereotactic ablative body radiation)
Terminated
- ALK-positive Non-small Cell Lung Cancer
- Ceritinib
- Stereotactic ablative body radiation
-
Dallas, TexasUT Southwestern Medical Center
Jan 31, 2023
NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer Metastatic
- Atezolizumab
- +5 more
- (no location specified)
Jan 18, 2023
Novel Grading System of Clinical Stage I Lung Adenocarcinoma
Recruiting
- Lung Adenocarcinoma
- +2 more
- PET/CT-based Radiomics Signature
-
Zunyi, Guizhou, China
- +3 more
Feb 12, 2023
Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Refractory Non-Small Cell Lung Cancer
- Daratumumab
- +2 more
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023
Intraoperative Frozen Section Pathology to Guide Surgical
Recruiting
- Lung Adenocarcinoma
- +2 more
- Surgical resection
-
Shanghai, Shanghai, ChinaFudan University Cancer Center
Mar 20, 2023
Lung Cancer Mutation Consortium Protocol
Active, not recruiting
- Adenocarcinoma of Lung, Stage IV
-
Aurora, ColoradoUniversity of Colorado Denver Cancer Center
Jan 30, 2023
Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)
Recruiting
- Lung Adenocarcinoma Stage III
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Aug 13, 2022
Adenocarcinoma of Lung Trial in United States (NovoTTF-200T System)
Not yet recruiting
- Adenocarcinoma of Lung
- NovoTTF-200T System
-
Basking Ridge, New Jersey
- +6 more
Mar 3, 2023
NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Phase I - Mirdametinib - Level 1
- +4 more
- (no location specified)
Jul 7, 2023
IASLC Grading System as a Predictor for EGFR-TKI Therapy
Completed
- Lung Cancer
- IASLC grading system
-
Shanghai, Please Select, ChinaChaoqiang Deng
Nov 9, 2023
Real-world Data of Afatinib Treatment in First-line Setting and
Active, not recruiting
- Non-squamous, Non-Small Cell Lung Cancer
-
Tokyo, JapanNippon Boehringer Ingelheim Co., Ltd.
Jan 9, 2023
Non-Small-Cell Lung Carcinoma, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma Trial (Liquid biopsy)
Not yet recruiting
- Non-Small-Cell Lung Carcinoma
- +2 more
- Liquid biopsy
- (no location specified)
Jan 24, 2023
Segmentectomy, Lung Adenocarcinoma Trial (Segmentectomy)
Not yet recruiting
- Segmentectomy
- Lung Adenocarcinoma
- Segmentectomy
- (no location specified)
Jan 29, 2023